Pay in 4 interest-free payments of $6.39 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
Safety Risks Associated with Certain Bulk Drug Substances Nominated for Use in Compounding
Cagrilintide Dose Escalation Studies Phase 2 trials evaluated multiple cagrilintide doses to identify the optimal balance between efficacy and tolerability: 0.3 mg weekly Minimal efficacy, excellent tolerability 0.6 mg weekly Moderate effects, good tolerability 1.2 mg weekly Strong efficacy, acceptable side effects 2.4 mg weekly Optimal efficacy-tolerability balance 4.5 mg weekly Excessive GI side effects outweighed benefits The 2.4 mg weekly dose emerged as the standard in phase 3 trials, providing substantial metabolic benefits while maintaining an acceptable side effect profile[6]
The higher concentration vials are designed for patients on maintenance doses who need more medication per injection
It has been shown that DSIP reduces the level of pain and works to improve depressive conditions
